COMPPARE – Proton and Photon Radiation in Prostate Cancer

A Comparative Study of Outcomes

COMPPARECOMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” This study, which is funded by the Patient-Centered Outcomes Research Institute (PCORI) and approved by the University of Florida Institutional Review Board (IRB 201801001; PI: Nancy Mendenhall, MD), will compare the quality of life, side effects, and cure rates for prostate cancer patients treated with proton therapy or photon therapy.

Patient enrollment in COMPPARE closed October 31, 2022. A total of 2,524 men between the ages of 30-80 across the US treated with either protons or photons are participating in the study. Participants will answer brief surveys regarding treatment choice, quality of life, and side effects for at least 3 years. In addition, proton therapy patients can choose to participate in a randomized trial that will evaluate whether quality of life, side effects, and prostate cancer cure rates differ between patients receiving the standard therapy versus a shorter therapy online with UF Health.

Study Goals

COMPPARE researchers hope to answer the following patient-centered questions:

  1. How likely are men to experience different quality of life issues with protons versus photons?
  2. How likely are men to experience different side effects with either treatment?
  3. Which treatment will result in a better cure rate?
  4. Is a shorter treatment regimen as safe and effective as the standard treatment regimen?

More Information

For more information, visit the COMPPARE website.


U.S. News and World Report

Nationally ranked in 6 adult specialties and 6 pediatric specialties and rated high performing in 4 adult specialties and 5 procedures and conditions.